Puma Biotechnology (PBYI) Competitors $7.08 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$7.08 0.00 (-0.07%) As of 05/22/2026 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBYI vs. ADMA, CTMX, TRDA, URGN, and CMPSShould you buy Puma Biotechnology stock or one of its competitors? MarketBeat compares Puma Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Puma Biotechnology include ADMA Biologics (ADMA), CytomX Therapeutics (CTMX), Entrada Therapeutics (TRDA), Urogen Pharma (URGN), and Compass Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry. PBYI vs. ADMAPBYI vs. CTMXPBYI vs. TRDAPBYI vs. URGNPBYI vs. CMPSHow does Puma Biotechnology compare to ADMA Biologics?Puma Biotechnology (NASDAQ:PBYI) and ADMA Biologics (NASDAQ:ADMA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment. Which has better valuation and earnings, PBYI or ADMA? ADMA Biologics has higher revenue and earnings than Puma Biotechnology. ADMA Biologics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPuma Biotechnology$228.40M1.58$31.11M$0.4814.75ADMA Biologics$510.17M3.74$146.93M$0.6812.12 Which has more volatility and risk, PBYI or ADMA? Puma Biotechnology has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Do insiders and institutionals hold more shares of PBYI or ADMA? 61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate PBYI or ADMA? ADMA Biologics has a consensus price target of $19.00, indicating a potential upside of 130.58%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts plainly believe ADMA Biologics is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00ADMA Biologics 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Does the media refer more to PBYI or ADMA? In the previous week, ADMA Biologics had 10 more articles in the media than Puma Biotechnology. MarketBeat recorded 10 mentions for ADMA Biologics and 0 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.00 beat ADMA Biologics' score of -0.13 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Overall Sentiment Puma Biotechnology Neutral ADMA Biologics Neutral Is PBYI or ADMA more profitable? ADMA Biologics has a net margin of 32.43% compared to Puma Biotechnology's net margin of 10.69%. ADMA Biologics' return on equity of 39.98% beat Puma Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Puma Biotechnology10.69% 20.30% 12.05% ADMA Biologics 32.43%39.98%28.08% SummaryADMA Biologics beats Puma Biotechnology on 12 of the 16 factors compared between the two stocks.How does Puma Biotechnology compare to CytomX Therapeutics?CytomX Therapeutics (NASDAQ:CTMX) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations. Does the media prefer CTMX or PBYI? In the previous week, CytomX Therapeutics had 4 more articles in the media than Puma Biotechnology. MarketBeat recorded 4 mentions for CytomX Therapeutics and 0 mentions for Puma Biotechnology. CytomX Therapeutics' average media sentiment score of 0.65 beat Puma Biotechnology's score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Overall Sentiment CytomX Therapeutics Positive Puma Biotechnology Neutral Which has preferable valuation and earnings, CTMX or PBYI? Puma Biotechnology has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$76.20M8.40-$17.37M-$0.41N/APuma Biotechnology$228.40M1.58$31.11M$0.4814.75 Is CTMX or PBYI more profitable? Puma Biotechnology has a net margin of 10.69% compared to CytomX Therapeutics' net margin of -166.40%. Puma Biotechnology's return on equity of 20.30% beat CytomX Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics-166.40% -36.61% -28.02% Puma Biotechnology 10.69%20.30%12.05% Do analysts prefer CTMX or PBYI? CytomX Therapeutics presently has a consensus target price of $12.10, indicating a potential upside of 221.81%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, CTMX or PBYI? CytomX Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Do institutionals & insiders believe in CTMX or PBYI? 67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 6.6% of CytomX Therapeutics shares are owned by insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryCytomX Therapeutics beats Puma Biotechnology on 9 of the 17 factors compared between the two stocks.How does Puma Biotechnology compare to Entrada Therapeutics?Puma Biotechnology (NASDAQ:PBYI) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation. Do institutionals and insiders have more ownership in PBYI or TRDA? 61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has higher valuation & earnings, PBYI or TRDA? Puma Biotechnology has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPuma Biotechnology$228.40M1.58$31.11M$0.4814.75Entrada Therapeutics$25.42M10.02-$143.75M-$3.99N/A Do analysts prefer PBYI or TRDA? Entrada Therapeutics has a consensus target price of $18.25, suggesting a potential upside of 178.20%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Entrada Therapeutics 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 Which has more risk & volatility, PBYI or TRDA? Puma Biotechnology has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market. Does the media favor PBYI or TRDA? In the previous week, Entrada Therapeutics had 5 more articles in the media than Puma Biotechnology. MarketBeat recorded 5 mentions for Entrada Therapeutics and 0 mentions for Puma Biotechnology. Entrada Therapeutics' average media sentiment score of 0.43 beat Puma Biotechnology's score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Puma Biotechnology Neutral Entrada Therapeutics Neutral Is PBYI or TRDA more profitable? Puma Biotechnology has a net margin of 10.69% compared to Entrada Therapeutics' net margin of -2,895.05%. Puma Biotechnology's return on equity of 20.30% beat Entrada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Puma Biotechnology10.69% 20.30% 12.05% Entrada Therapeutics -2,895.05%-51.22%-42.20% SummaryPuma Biotechnology beats Entrada Therapeutics on 9 of the 17 factors compared between the two stocks.How does Puma Biotechnology compare to Urogen Pharma?Urogen Pharma (NASDAQ:URGN) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment. Which has more volatility & risk, URGN or PBYI? Urogen Pharma has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Is URGN or PBYI more profitable? Puma Biotechnology has a net margin of 10.69% compared to Urogen Pharma's net margin of -94.83%. Puma Biotechnology's return on equity of 20.30% beat Urogen Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Urogen Pharma-94.83% N/A -62.85% Puma Biotechnology 10.69%20.30%12.05% Do insiders and institutionals have more ownership in URGN or PBYI? 91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 4.7% of Urogen Pharma shares are owned by insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has better earnings and valuation, URGN or PBYI? Puma Biotechnology has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUrogen Pharma$109.79M12.82-$153.49M-$2.75N/APuma Biotechnology$228.40M1.58$31.11M$0.4814.75 Does the media prefer URGN or PBYI? In the previous week, Urogen Pharma had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 1 mentions for Urogen Pharma and 0 mentions for Puma Biotechnology. Urogen Pharma's average media sentiment score of 0.26 beat Puma Biotechnology's score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the media. Company Overall Sentiment Urogen Pharma Neutral Puma Biotechnology Neutral Do analysts prefer URGN or PBYI? Urogen Pharma currently has a consensus price target of $36.67, suggesting a potential upside of 26.92%. Given Urogen Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Urogen Pharma is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Urogen Pharma 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryUrogen Pharma beats Puma Biotechnology on 9 of the 17 factors compared between the two stocks.How does Puma Biotechnology compare to Compass Pathways?Puma Biotechnology (NASDAQ:PBYI) and Compass Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk. Which has preferable earnings and valuation, PBYI or CMPS? Puma Biotechnology has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPuma Biotechnology$228.40M1.58$31.11M$0.4814.75Compass PathwaysN/AN/A-$287.86M-$3.15N/A Do analysts recommend PBYI or CMPS? Compass Pathways has a consensus target price of $20.58, suggesting a potential upside of 74.29%. Given Compass Pathways' stronger consensus rating and higher possible upside, analysts clearly believe Compass Pathways is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Compass Pathways 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.93 Which has more risk & volatility, PBYI or CMPS? Puma Biotechnology has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.39, meaning that its share price is 139% more volatile than the broader market. Do institutionals & insiders hold more shares of PBYI or CMPS? 61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 2.8% of Compass Pathways shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor PBYI or CMPS? In the previous week, Compass Pathways had 13 more articles in the media than Puma Biotechnology. MarketBeat recorded 13 mentions for Compass Pathways and 0 mentions for Puma Biotechnology. Compass Pathways' average media sentiment score of 0.60 beat Puma Biotechnology's score of 0.00 indicating that Compass Pathways is being referred to more favorably in the news media. Company Overall Sentiment Puma Biotechnology Neutral Compass Pathways Positive Is PBYI or CMPS more profitable? Puma Biotechnology has a net margin of 10.69% compared to Compass Pathways' net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Compass Pathways' return on equity.Company Net Margins Return on Equity Return on Assets Puma Biotechnology10.69% 20.30% 12.05% Compass Pathways N/A -31.07%-11.40% SummaryPuma Biotechnology beats Compass Pathways on 9 of the 16 factors compared between the two stocks. Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBYI vs. The Competition ExportMetricPuma BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$360.36M$3.37B$6.45B$12.34BDividend YieldN/A2.26%2.76%5.28%P/E Ratio14.7518.7421.2225.65Price / Sales1.58323.98553.9286.28Price / Cash8.49125.1743.4956.67Price / Book2.817.0910.377.14Net Income$31.11M$24.45M$3.57B$335.98M7 Day Performance3.96%5.45%6.01%3.56%1 Month Performance-6.10%2.43%3.52%2.54%1 Year Performance119.20%62.98%34.13%35.05% Puma Biotechnology Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBYIPuma Biotechnology1.2957 of 5 stars$7.08flatN/A+119.2%$360.36M$228.40M14.75200ADMAADMA Biologics4.5436 of 5 stars$8.38+1.3%$19.00+126.7%-59.6%$1.92B$510.17M12.32530CTMXCytomX Therapeutics3.1359 of 5 stars$3.50-3.0%$12.78+265.1%+68.6%$614.37M$76.20MN/A170TRDAEntrada Therapeutics3.9242 of 5 stars$5.89-7.7%$18.25+209.8%-12.5%$247.68M$5.74MN/A110URGNUrogen Pharma3.3458 of 5 stars$28.58-0.7%$36.67+28.3%+589.5%$1.40B$109.79MN/A200Gap Up Related Companies and Tools Related Companies ADMA Biologics Competitors CytomX Therapeutics Competitors Entrada Therapeutics Competitors Urogen Pharma Competitors Compass Pathways Competitors Phibro Animal Health Competitors Bicara Therapeutics Competitors Biohaven Competitors SELLAS Life Sciences Group Competitors WAVE Life Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBYI) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
